Preapproval Safe Harbor Should Extend 18 Months, Payers And Sponsors Say
Executive Summary
Manufacturers should be allowed to talk to payer representatives involved in financial forecasting about a new drug well before FDA approval, group led by Academy of Managed Care Pharmacy says.
You may also be interested in...
'Safe Harbor' For Preapproval Information Exchange To Get Legislative Push
US Academy of Managed Care Pharmacy is developing language to protect exchange of clinical and economic information on pipeline products between manufacturers and healthcare decision-makers; safe harbor could find a home in legislation reauthorizing FDA user fee programs.
Alzheimer’s Drugs and Medicare: A Case For Pre-Approval Discussions
Medicare's Part D plan bidding schedule and uncertainty over the Alzheimer’s drug pipeline is putting plan sponsors in a difficult situation as they contemplate their 2018 bids.
FDA's Off-Label Communication Changes Should Start With Payers – PhRMA
PhRMA Senior Counsel Jeffrey Francer offers three-step reform approach to loosening FDA’s restrictions, beginning with the 'low-hanging fruit' of talking with payers.